周六报道，Abivax在ECCO 2026上公布了Obefazimod在临床前模型中的首个抗纤维化数据，以及第1周的快速症状反应和安全性分析

2026-02-23 14:55

22 abstracts presented at European Crohn's and Colitis Organization's (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod's potential in inflammatory bowel disease
Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn's disease
A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials demonstrates a favorable safety profile with rates of serious treatment emergent adverse events and study discontinuation similar to placebo
Symptomatic response of obefazimod was observed as early as week 1 (first time point evaluated) with symptomatic remission observed at week 2 (nominally significant p-value <0.05) in a pooled analysis of ABTECT-1 and ABTECT-2
Biomarker data from ABTECT-1 and ABTECT-2 induction trials indicate upregulation of miR-124 and reduction of key inflammatory cytokines (IL-17A and IL-6) toward homeostatic levels